AI Medical Compendium Topic

Explore the latest research on artificial intelligence and machine learning in medicine.

Neoadjuvant Therapy

Showing 131 to 140 of 189 articles

Clear Filters

Deep learning-based radiomic features for improving neoadjuvant chemoradiation response prediction in locally advanced rectal cancer.

Physics in medicine and biology
Radiomic features achieve promising results in cancer diagnosis, treatment response prediction, and survival prediction. Our goal is to compare the handcrafted (explicitly designed) and deep learning (DL)-based radiomic features extracted from pre-tr...

Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy.

Breast (Edinburgh, Scotland)
In patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy (NAC), some patients achieve a complete pathologic response (pCR), some achieve a partial response, and some do not respond at all or even progress. Accurate predicti...

MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer.

European journal of radiology
PURPOSE: To develop and validate an Artificial Intelligence (AI) model based on texture analysis of high-resolution T2 weighted MR images able 1) to predict pathologic Complete Response (CR) and 2) to identify non-responders (NR) among patients with ...

Predicting Ewing Sarcoma Treatment Outcome Using Infrared Spectroscopy and Machine Learning.

Molecules (Basel, Switzerland)
BACKGROUND: Improved outcome prediction is vital for the delivery of risk-adjusted, appropriate and effective care to paediatric patients with Ewing sarcoma-the second most common paediatric malignant bone tumour. Fourier transform infrared (FTIR) sp...

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery
OBJECTIVE: We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess t...